Any system which mesures the performance of Cytopathology Laboratories demands an established Internal Quality Control Program. The objective of this research is to identify the data of the Program and the performance of the cytotechnologists. We have reviewed 48,355 gynecologic cytopathology reports from cytotechnologists and cytopathologists for 21 months. We have identified 2,299 abnormal cases submitted the cytopathologist of which 1,132 were confirmed; 2,973 cases classified as high-risk were informed and 998 abnormal cases were identified. The revision of 10% of the negative cytologies represented 3,180 cases, of which 77 abnormal reports were identified. These encompassed 1,176 Ascus, 60 Agus, 819 Nic I/HPV, 85 Nic II, 33 Nic III, 11 squamous cell carcinomas, 17 adenocarcinomas, 5 Vain I and 1 Vain III. The Ascus/Agus were 56% of the cases and 44% corresponded to the other lesions. The 4.56% of abnormal cases were in accordance to the values proposed by Cardin (3-5%), the Bethesda System (4-6%) and Kurman et al. (5%) (4, 6, 7). The cytopathologists reviewed 17.48% of the cases (n = 8,452). Of the 77 abnormal cases (0.16% of the total) which were identified in the re-screening, 59 (0.12%) were Ascus, 6 (0.01%) were Agus and 12 (0.02%) were Nic I. This research shows the results of the Internal Quality Assurance developed in a private laboratory and give relevant information for planning a uterocervical cancer prevention program.
Quality control program; Quality; Gynecological; cytopathology
